Annuncio pubblicitario
Italia markets open in 7 hours 43 minutes
  • Dow Jones

    38.111,48
    -330,06 (-0,86%)
     
  • Nasdaq

    16.737,08
    -183,50 (-1,08%)
     
  • Nikkei 225

    38.054,13
    -502,74 (-1,30%)
     
  • EUR/USD

    1,0835
    0,0000 (-0,00%)
     
  • Bitcoin EUR

    63.114,83
    +729,06 (+1,17%)
     
  • CMC Crypto 200

    1.429,05
    -26,81 (-1,84%)
     
  • HANG SENG

    18.230,19
    -246,82 (-1,34%)
     
  • S&P 500

    5.235,48
    -31,47 (-0,60%)
     

Voting Rights and Shares Capital of the Company

Nanobiotix S.A.
Nanobiotix S.A.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date

Number of Shares Outstanding



Total number of voting rights

Total voting rights, theoretical1

Total voting rights,
exercisable2

September 30, 2023

36,190,019

37,905,821

37,883,703

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

ANNUNCIO PUBBLICITARIO

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix

 

 

 

 



Nanobiotix Communications
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com



Nanobiotix Investor Relations
Craig West
SVP, Investor Relations
+1 (617) 583-0211 
investors@nanobiotix.com

 

 

 

 

Media Relations

 

 

France – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com

LifeSci Advisors 
Ligia Vela-Reid 
+44 (0) 7413825310 
lvela-reid@lifesciadvisors.com

 

 




1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.


Attachment